In this blog, we discuss PPD, what different agencies actually care about, and how to navigate CTT language in an ever-changing regulatory landscape.
With the release of Blur™ 2.10, Instem is introducing a broad set of enhancements across CSR anonymization, data de-identification, risk simulation, administration, performance, and security.
This blog examines how clinical trial transparency regulations are evolving and what organizations can do to keep up with expectations.
BOSTON, USA – 21 April 2026: d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades...
Read this blog to learn about the challenges and best practices when using open-source solutions in clinical trial data analytics.
In this blog, we answer a number of recurring questions about validation, reproducibility, governance, and risk while using R for clinical data analytics.
